Business Context and Reporting Period
This Form 8-K filing by Magenta Therapeutics, Inc. (MGTA) reports on the Annual Meeting of Stockholders held on June 28, 2022. The registrant is a Delaware corporation headquartered in Cambridge, Massachusetts, and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results rather than financial performance.
Material Changes and Voting Results
The filing details the final voting outcomes for two proposals submitted to stockholders:
- Proposal 1: Election of Class I Directors
- Thomas O. Daniel, M.D. was elected with 29,064,311 votes for, 7,962,396 votes withheld, and 16,120,189 broker non-votes.
- Amy Lynn Ronneberg was elected with 27,364,344 votes for, 9,662,363 votes withheld, and 16,120,189 broker non-votes.
- Both directors will serve until the 2025 annual meeting.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Voting results: 52,877,344 votes for, 249,235 votes against, and 20,317 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items. The document serves strictly as a disclosure of the Annual Meeting results.
Investor Verification Checklist
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Review the Definitive Proxy Statement on Schedule 14A (filed May 2, 2022) for detailed biographies of the newly elected directors.
- Confirm the engagement letter terms with KPMG LLP for the 2022 fiscal year.
- Check subsequent filings for the company's financial status, as this 8-K contains no financial data.